Compare GETY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | VTYX |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 990.9M |
| IPO Year | N/A | 2021 |
| Metric | GETY | VTYX |
|---|---|---|
| Price | $1.31 | $13.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | $5.01 | ★ $13.50 |
| AVG Volume (30 Days) | 1.7M | ★ 5.6M |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $946,327,000.00 | N/A |
| Revenue This Year | $2.53 | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.10 | N/A |
| 52 Week Low | $1.20 | $0.78 |
| 52 Week High | $3.21 | $25.00 |
| Indicator | GETY | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 75.82 |
| Support Level | $1.26 | $7.08 |
| Resistance Level | $1.34 | $15.34 |
| Average True Range (ATR) | 0.06 | 0.46 |
| MACD | 0.01 | 0.40 |
| Stochastic Oscillator | 64.10 | 82.26 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.